Q16H (p.Gln16His) variant of ABL2 (Tyrosine-protein kinase ABL2)
Q16H (p.Gln16His) in ABL2 (Tyrosine-protein kinase ABL2) is a missense change. Clinical records from UniProt describe it as variant assessed as somatic; moderate impact. The available variant effect predictions contribute to a CATVariant prioritization score of 0.39 / 1. The record also includes population frequency data.
Q16H (p.Gln16His) variant details
- p.Gln16His
- NCI-TCGA Cosmic COSV1008
- cosmic curated COSV10085
- Variant assessed as somatic; moderate impact.
- Missense
- Variant Prioritization Score for Impact Estimate 0.392
- REVEL 0.16
- CADD 23.50
- PolyPhen-2 0.13
- SIFT 0.02
- UniProt: Variant assessed as somatic; moderate impact.
- Population evidence available